The packet lists no genes, inheritance pattern or molecular mechanism for acoustic neuroma, so the genetic basis is not described here. The definition states that the tumor begins in the Schwann cells that produce myelin around the acoustic nerve.

Diagnostic methods and criteria are not certified in this packet, and no GeneReviews diagnosis content is attached for this condition.

Treatment coverage is not certified in this packet. No approved treatments are recorded for acoustic neuroma in the packet's FDA-approved treatment field, and no foundational therapies or GeneReviews management content are provided.

Prognosis and natural history are not certified in this packet.

The packet lists clinical trial records on ClinicalTrials.gov associated with acoustic neuroma and vestibular schwannoma. Records with current status include NCT01199978 (Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma; Phase 2; active, not recruiting; Massachusetts General Hospital), NCT04859335 (Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma; recruiting; University Hospital, Toulouse), NCT03795675 (CI Following VS Removal or Labyrinthectomy; active, not recruiting; Ohio State University) and NCT06517888 (Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma; Phase 1; recruiting; Akouos, Inc.). The packet's trial summary lists drug therapy, procedural interventions, medical devices and other interventions as intervention types. Active clinical trials for this condition are listed on ClinicalTrials.gov.